Commercial Performance of Tafasitamab
In the first nine months of 2022, Monjuvi sales reached € 60.2 million (Q3 2021: € 46.4 million), driven
primarily by demand where we saw the highest demand in the first nine months since launch. Compared to
Q3 2021, the sales in Q3 2022 rose by 18% (based on sales in €) and amounted to € 21.9 million (Q3 2021:
€ 18.6 million). MorphoSys and Incyte continue to see a high penetration in the community setting driving
70% of the sales with the balance coming from the academic setting. Since launch, the Company, along with
its partner Incyte, has in aggregate received orders from 1,350 treatment sites. During the third quarter 2022,
greater than 550 accounts ordered with more than 80% of those accounts representing repeat orders. While
we continue to see a positive trend year-over-year, we recognize that the competition has increased as
additional second-line treatment options for relapsed or refractory diffuse large B-cell lymphoma have been
recently approved
(van de website)